Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry
- 25 November 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 20 (2) , 183-192
Abstract
Objectives To assess the role of short-term response to first anti-TNF in long-term prediction of disability. Methods In nationwide registry ATTRA, we identified ankylosing spondylitis patients starting anti-TNF between 01/2003 and 12/2016. Full disability and work impairment (WI; WPAI questionnaire) were predicted via the Cox- and lagged-parameter mixed-effect regression. Results 2,274 biologicals-naïve patients newly indicated to anti-TNF were prospectively followed (6,333 patient-years; median follow-up 1.9 years). Reaching BASDAI < 4 (77.4%) and ASDAS-CRP < 2.1 (61.1%) after 3 months of anti-TNF both decreased the risk of future disability by ≈2.5-fold. ASDAS-CRP < 2.1 predicted non-disability better than BASDAI < 4 & CRP < 5 mg/L (p=0.032). BASDAI < 4 & CRP < 5 mg/L was comparable to BASDAI < 4 (p=0.941) and to BASDAI change by > 50% or by > 2 points (p=0.902). ASDAS-CRP change > 1.1 and > 2.0 both failed to predict non-disability. Once on anti-TNF therapy, the strongest predictor of WI was Pain (SF36). Yearly increase in indirect costs remains below €3,000 in those reaching ASDAS-CRP < 2.1. Conclusions Low disease activity measured by ASDAS-CRP ≤ 2.1 should be used to measure the outcome of new anti-TNF therapy. Continuous WI could be decreased through pain management.Keywords
This publication has 40 references indexed in Scilit:
- Opinion of patients with ankylosing spondylitis on risk factors impairing their quality of lifeRheumatology International, 2012
- Endorsement of Definitions of Disease Activity States and Improvement Scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10The Journal of Rheumatology, 2011
- Work Disability in Patients with Ankylosing Spondylitis in NorwayThe Journal of Rheumatology, 2011
- EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatologyAnnals of the Rheumatic Diseases, 2010
- Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal costAnnals of the Rheumatic Diseases, 2010
- The value of productivity: human-capital versus friction-cost methodAnnals of the Rheumatic Diseases, 2010
- Work Disability in Patients with Ankylosing SpondylitisThe Journal of Rheumatology, 2009
- Work disability in ankylosing spondylitis: differences among working and work-disabled patientsClinical Rheumatology, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993